Resultado de búsqueda
Pipeline – Revolution Medicines. RMC-6236 is an investigational, oral, RAS (ON) multi-selective non-covalent inhibitor designed to treat patients with cancers driven by a wide range of common RAS mutations. For more information about our RMC-6236 clinical trials, visit Clinical Trials.gov.
At Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines.
Background. Preclinical data for RMC-6236. Clinical trial design and initial toxicity and efficacy data for RMC-6236-001 trial. Future directions for RAS inhibition in pancreatic cancer. KRAS. mutant alleles by cancer type. KRAS mutations are most common in the three leading causes of cancer death in US:
The Phase 1/1b trial ( NCT06040541) is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-9805 in patients with advanced solid tumors harboring the KRAS G12D mutation.
4 de dic. de 2023 · Revolution Medicines’ RAS(ON) inhibitors completely differ from the currently approved G12C RAS(OFF) inhibitors mechanistically, which may bring new hope to KRAS precision therapy.
The scientific paper demonstrates that the RAS(ON) multi-selective inhibitor RMC-7977 (a preclinical tool compound representative of the investigational drug candidate RMC-6236) exhibited robust and durable anti-tumor activity in multiple preclinical models of KRAS-mutated NSCLC.
28 de jun. de 2022 · Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
